Activity Overview
This educational activity is an archive of the live presentation held on April 20, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, and other health care providers involved in the management of gliomas.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate current classification criteria and diagnostic strategies for identifying adult and pediatric patients with glioma
- Incorporate genetic and molecular information to classify gliomas and develop personalized treatment plans accurately
- Evaluate the data for recent advancements in targeted agents, immunotherapies, and other innovative treatment methods for treating patients with gliomas
- Identify strategies to integrate targeted therapies, immunotherapies, and novel emerging treatment approaches for managing pediatric patients with gliomas.
Vinay K. Puduvalli, MD
Professor and Chair, Department of Neuro-Oncology
Co-Director, Cancer Neuroscience Program
Co-Director, NeuroHealth Initiative
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Boehringer Ingelheim, Guidepoint, Novocure, Servier Pharmaceuticals, Tango Therapeutics, Telix Pharmaceuticals, Orbus Therapeutics
Manmeet Ahluwalia, MD, MBA
Professor of Translational Medicine
Herbert Wertheim College of Medicine, Florida International
University
Fernandez Family Foundation Endowed Chair in Cancer Research
Chief of Medical Oncology
Chief Scientific Officer and Deputy Director
Baptist Health Miami Cancer Institute
Miami, FL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AlloVir, Apollomics, Autem Therapeutics, Bayer, Bugworks; Research, Equillium, GT Medical Technologies, Incyte, Novocure, Recordati, Servier Pharmaceuticals, VBI Vaccines, Xoft; Grant/ Research Funding: Incyte, Pfizer; Ownership interests in publicly traded companies: Live AI, MimiVax, Ryght AI, TriSalus Life Sciences
Ashley S. Margol, MD, MS
Associate Professor of Clinical Pediatrics
Keck School of Medicine of the University of Southern California
Project Co-Leader, Pediatric Neuro-Oncology Consortium
Director, Brain Tumor Center and Neuro-Oncology Program
Director, Neuro-Oncology Fellowship Program
Children’s Hospital Los Angeles
Los Angeles, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Day One Biopharmaceuticals, Jazz Pharmaceuticals; Grant/Research Funding: Regeneron
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here